hackint0sh/New-Dataset huggingface dataset:
In order to determine the effect of IC application in household tanks, the dengue incidence and entomological indices are compared in the study clusters. The data are analysed under the difference in difference approach. Additionally, the acceptance of IC in the intervened communities and local health services is determined. conditions: Dengue conditions: Vector Borne Diseases conditions: Arbovirus Infections conditions: Zika conditions: Chikungunya Fever studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A cluster randomised trial for the application of a new vector control tool (insecticide coating of water containers) was conducted in the metropolitan area of Cúcuta, Colombia. Each cluster comprising approximately 2,000 dwellings. primaryPurpose: PREVENTION masking: NONE count: 35000 type: ACTUAL name: Insecticide Coating INESFLY measure: Change of dengue incidence for 12 months measure: Change of vector densities estimated through larval and pupal indices. sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Instituto Departamental de Salud de Norte de Santander city: Cúcuta state: Norte De Santander zip: 540001 country: Colombia lat: 7.89391 lon: -72.50782 facility: Centre for Medicine and Society city: Freiburg state: Baden-Württemberg zip: 79098 country: Germany lat: 47.9959 lon: 7.85222 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2019-03-11 uploadDate: 2024-02-12T15:19 filename: Prot_000.pdf size: 2263350 typeAbbrev: SAP hasProtocol: False hasSap: True hasIcf: False label: Statistical Analysis Plan date: 2019-03-11 uploadDate: 2024-02-12T15:19 filename: SAP_001.pdf size: 768947 hasResults: False
nctId: NCT06268678 id: 4539513 briefTitle: The Effect of Menstrual Cycle Phase on Muscle Protein Synthesis overallStatus: RECRUITING date: 2023-12-08 date: 2025-01-30 date: 2025-01-30 date: 2024-02-20 date: 2024-02-20 name: University of Exeter class: OTHER name: Pvolve briefSummary: The combination of dietary protein ingestion and resistance exercise are essential to increase muscle protein synthesis. The vast majority of studies assessing protein intake following resistance exercise in young adults has been conducted exclusively in men or in studies where both men and women are assessed. The increase in muscle mass is thought to be impacted by sex hormones that fluctuate across different phases of the menstrual cycle. However, the effect of menstrual cycle phase on muscle protein synthesis following exercise is not known. conditions: Menstrual Cycle Phase conditions: Muscle Protein Synthesis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Randomised cross-over design. primaryPurpose: BASIC_SCIENCE masking: NONE count: 15 type: ESTIMATED name: Phase of the menstrual cycle measure: Muscle protein synthesis measure: Plasma amino acid kinetics measure: Serum insulin concentrations measure: Sex hormone concentrations measure: Energy expenditure sex: FEMALE minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: University of Exeter status: RECRUITING city: Exeter state: Devon zip: EX1 2LT country: United Kingdom name: Marianna Apicella role: CONTACT lat: 50.7236 lon: -3.52751 hasResults: False
nctId: NCT06268665 id: UCDCC307 briefTitle: Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy overallStatus: NOT_YET_RECRUITING date: 2024-02-28 date: 2027-02 date: 2027-06 date: 2024-02-20 date: 2024-02-20 name: Eve Rodler class: OTHER briefSummary: This is a single institution phase II randomized study evaluating the potential benefits of a supplement, tart cherry juice at high- versus low-doses, to prevent taxane induced peripheral neuropathy in breast and ovarian cancer patients undergoing paclitaxel chemotherapy.
Eligible participants enrolled onto the study will be block randomized in a 1:1 allocation to either the tart cherry juice high-dose group (Arm 1) or the tart cherry juice low-dose group (Arm 2). conditions: Breast Cancer conditions: Breast Cancer Stage I conditions: Breast Cancer Stage II conditions: Breast Cancer Stage III conditions: Breast Cancer Stage IV conditions: Invasive Breast Cancer conditions: Ovarian Cancer conditions: Ovarian Cancer Stage 1 conditions: Ovarian Cancer Stage II conditions: Ovarian Cancer Stage III conditions: Ovarian Cancer Stage IV conditions: Ovarian Cancer Stage IA conditions: Ovarian Cancer Stage IB conditions: Ovarian Cancer Stage IC conditions: Ovarian Cancer Stage 2 conditions: Ovarian Cancer Stage 3 conditions: Ovarian Cancer Stage IIIb conditions: Ovarian Cancer Stage IIIC conditions: Breast Cancer Stage IIIA conditions: Breast Cancer Invasive conditions: Breast Cancer, Stage IA conditions: Breast Cancer, Stage IB conditions: Breast Cancer Stage IIA conditions: Breast Cancer Stage IIB conditions: Breast Cancer Stage IIIB conditions: Breast Cancer Stage IIIc conditions: Cancer, Breast conditions: Tumors, Breast conditions: Mammary Cancer conditions: Mammary Carcinoma conditions: Breast Carcinoma conditions: Breast Neoplasm conditions: Malignant Breast Neoplasm conditions: Malignant Tumor of Breast conditions: Cancer of Ovary conditions: Ovary Cancer conditions: Ovary Neoplasm studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 86 type: ESTIMATED name: Tart Cherry Juice measure: Efficacy of tart cherry juice supplementation in the prevention of paclitaxel-induced peripheral neuropathy (PIPN) in breast and ovarian cancer patients undergoing treatment with paclitaxel-based chemotherapy. measure: Compare the effectiveness of high- dose and low-dose tart cherry juice supplement in reducing the severity of PIPN in breast and ovarian cancer patients undergoing treatment with paclitaxel-based chemotherapy. measure: Assess the impact of tart cherry juice on dose delivery of taxane chemotherapy. measure: Tolerability of daily intake of high-dose and low-dose tart cherry juice. measure: Safety profile of daily intake of high-dose and low-dose tart cherry juice. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of California Davis Comprehensive Cancer Center city: Sacramento state: California zip: 95827 country: United States name: Eve Rodler, MD role: CONTACT phone: 916-734-5409 email: erodler@ucdavis.edu name: Eve Rodler, MD role: PRINCIPAL_INVESTIGATOR lat: 38.58157 lon: -121.4944 hasResults: False
nctId: NCT06268652 id: B2023-686-01 briefTitle: Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer overallStatus: RECRUITING date: 2024-01-15 date: 2026-02-15 date: 2028-01-15 date: 2024-02-20 date: 2024-02-20 name: Sun Yat-sen University class: OTHER briefSummary: This multicenter, open-label, randomized phase III trial is designed to study the efficacy and safety of organoid-guided personalized treatment （OGPT）versus treatment of physician's choice (TPC) in previously treated refractory breast cancer. conditions: Breast Cancer conditions: Refractory Breast Carcinoma studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 302 type: ESTIMATED name: Organoid-guided personalized treatment name: Gemcitabine name: Capecitabine name: Vinorelbine name: Eribulin measure: Progression-free survival (PFS) measure: Overall Survival (OS) measure: Objective Response Rate (ORR) measure: Duration of Response (DOR) measure: Disease Control Rate (DCR) measure: Incidence of Treatment-related Adverse Events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yanxia Shi status: RECRUITING city: Guangzhou state: None Selected zip: 510060 country: China name: Yanxia Shi role: CONTACT phone: 020-87343368 email: shiyx@sysucc.org.cn lat: 23.11667 lon: 113.25 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-12-12 uploadDate: 2024-01-23T03:33 filename: Prot_000.pdf size: 469389 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2023-12-12 uploadDate: 2024-01-23T02:42 filename: ICF_001.pdf size: 330483 hasResults: False
nctId: NCT06268626 id: H22-02426 id: F22-01302 type: OTHER_GRANT domain: Canadian Institutes of Health Research (CIHR) id: F21-03695 type: OTHER_GRANT domain: Canadian Institutes of Health Research (CIHR) briefTitle: Detection of Endometrial Cancer Through Risk Modelling acronym: DETECTR overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-01 date: 2027-01 date: 2024-02-20 date: 2024-02-20 name: University of British Columbia class: OTHER name: Canadian Institutes of Health Research (CIHR) briefSummary: The goal of this study is to combine information on risk factors from health questionnaires with minimally invasive biological tests (vaginal DNA and microbiome swabs, pH, hormones) to predict the risk of endometrial cancer (EC), better understand progression of the disease, and identify opportunities for intervention.
This study will recruit patients who are already scheduled to undergo diagnostic evaluation for abnormal uterine bleeding via endometrial biopsy. In Part A, consented participants will be asked to fill out an online risk factor questionnaire. Samples will be collected by the gynecologist at the biopsy appointment. After biopsy results are obtained, all samples from participants diagnosed with EC or precursors, plus a random subset with benign results, will be selected to be sequenced and analyzed.
In Part B, that subset of selected non-malignant participants, based on biopsy, will be invited to take part in lifestyle tracking using a Fitbit, questionnaires, and to provide another round of at-home vaginal samples to identify any persistent genetic mutations or microbiome alterations 6-8 months later. conditions: Endometrial Cancer studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED measure: Association Between Risk Factor Data and Endometrial Cancer and It's Precursors. measure: Change in Risk Prediction of Endometrial Cancer When Mutation and Microbiome Data Is Combined With Traditional Risk Factors, Compared to Traditional Risk Factors Alone. measure: Persistence of Mutations and Microbiome Alterations in Participants With Endometrial Hyperplasia. sex: FEMALE minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: VGH Research Pavilion city: Vancouver state: British Columbia zip: V5Z 1M9 country: Canada name: Aline Talhouk, PhD role: CONTACT phone: +1 (604) 875-4111 phoneExt: 21365 email: a.talhouk@ubc.ca name: Elise Abi Khalil, PhD role: CONTACT phone: +1 (604) 875-4111 phoneExt: 21369 email: elise.abikhalil@ubc.ca name: Aline Talhouk, PhD role: PRINCIPAL_INVESTIGATOR lat: 49.24966 lon: -123.11934 hasResults: False
nctId: NCT06268613 id: SB27-1005 briefTitle: A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy overallStatus: RECRUITING date: 2024-01-16 date: 2025-05 date: 2025-12 date: 2024-02-20 date: 2024-04-19 name: Samsung Bioepis Co., Ltd. class: INDUSTRY briefSummary: The goal of this clinical trial is to compare the amount of study drug in patients' blood to confirm that SB27 works in the same way as EU and US sourced Keytruda in early or locally advanced non-small cell lung cancer (NSCLC) patients who underwent surgery and adjuvant chemotherapy. The main question it aims to answer is:
Researchers will compare 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) to see if SB27 works in the same way as EU and US sourced Keytruda. conditions: Non-small Cell Lung Cancer Stage II conditions: Non-small Cell Lung Cancer Stage IIIA studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 135 type: ESTIMATED name: SB27 name: EU sourced Keytruda name: US sourced Keytruda measure: Area Under the Concentration-time Curve (AUC) over the Dosing Interval at Cycle 1 measure: Area Under the Concentration-time Curve (AUC) over the Dosing Interval at Cycle 6 measure: Disease-free Survival measure: Overall Survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: SB Investigative Site status: RECRUITING city: Busan country: Korea, Republic of lat: 35.10278 lon: 129.04028 facility: SB Investigative Site status: RECRUITING city: Daegu country: Korea, Republic of lat: 35.87028 lon: 128.59111 facility: SB Investigative Site status: RECRUITING city: Hwasun country: Korea, Republic of lat: 35.06125 lon: 126.98746 facility: SB Investigative Site status: RECRUITING city: Jinju country: Korea, Republic of lat: 35.19278 lon: 128.08472 facility: SB Investigative Site status: RECRUITING city: Seongnam country: Korea, Republic of lat: 37.43861 lon: 127.13778 facility: SB Investigative Site status: RECRUITING city: Seoul country: Korea, Republic of lat: 37.566 lon: 126.9784 facility: SB Investigative Site status: RECRUITING city: Suwon country: Korea, Republic of lat: 37.29111 lon: 127.00889 facility: SB Investigative Site status: RECRUITING city: Szczecin country: Poland lat: 53.42894 lon: 14.55302 facility: SB Investigative Site status: RECRUITING city: Leganés state: Madrid country: Spain lat: 40.32718 lon: -3.7635 facility: SB Investigative Site status: RECRUITING city: A Coruña state: Santiago De Compostela country: Spain lat: 43.37135 lon: -8.396 facility: SB Investigative Site status: RECRUITING city: Jaén country: Spain lat: 37.76922 lon: -3.79028 facility: SB Investigative Site status: RECRUITING city: Málaga country: Spain lat: 36.72016 lon: -4.42034 hasResults: False
nctId: NCT06268600 id: NPC-Thyroid function briefTitle: The Protection of Thyroid Function in IMRT for Nasopharyngeal Carcinoma overallStatus: RECRUITING date: 2019-01-01 date: 2024-11-30 date: 2025-11-30 date: 2024-02-20 date: 2024-04-11 name: Jiangxi Provincial Cancer Hospital class: OTHER briefSummary: This study aimed to reduce radiation-induced thyroid injury without compromising control of the cervical region by optimizing the delineation of the cervical lymph node drainage area. conditions: Nasopharyngeal Carcinoma conditions: Nasopharyngeal Cancer conditions: Hypothyroidism studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: FACTORIAL primaryPurpose: TREATMENT masking: NONE count: 320 type: ESTIMATED name: Modified neck target volume delineation measure: Regional Recurrence-free Survival measure: Radiation-induced hypothyroidism measure: Overall Survival measure: Progression-free Survival sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Nasopharyngeal Carcinoma, Jiangxi Cancer Hospital status: RECRUITING city: Nanchang state: None Selected zip: 330029 country: China name: Tianzhu Lu role: CONTACT phone: 8615270186250 email: lutianzhu2008@163.com role: CONTACT phoneExt: Li email: lijingao@hotmail.com name: Jingao Li, PhD role: PRINCIPAL_INVESTIGATOR name: Xiaochang Gong, PhD role: SUB_INVESTIGATOR lat: 28.68396 lon: 115.85306 hasResults: False
nctId: NCT06268587 id: 2023/80 briefTitle: A Before and After Study Studying the Impact of an Analgesia Protocol After Discharge From Outpatient Surgery overallStatus: COMPLETED date: 2019-09-01 date: 2022-02-28 date: 2022-02-28 date: 2024-02-20 date: 2024-02-20 name: Centre Hospitalier Universitaire de Liege class: OTHER briefSummary: The goal of this before and after study is to measure the effectiveness of a home analgesia protocol after outpatient surgery in a tertiary hospital. The main question it aims to answer is:
The participants are divided into two groups. The control group leaves the hospital with instructions and prescriptions. The experimental group leaves the hospital with instructions, analgesics for a maximum of two days with detailed dosages and an explanatory booklet on postoperative pain. conditions: Postoperative Pain conditions: Outpatient Surgery studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1423 type: ACTUAL name: Measure the impact of the home analgesia protocol on the proportion of patients with a VAS &gt; 3/10 on day one and who did not take analgesics. measure: Measure the impact of the protocol on the proportion of patients with a pain greater than 3/10 on a Visual Analogue Scale at day one and who did not take the analgesics. measure: Measure the adequacy of post-op analgesics by measuring the proportion of patients with a Visual Analogue Scale < or = 3/10 on day one for each group measure: Measure the impact of the protocol on the occurrence of nausea and vomiting on day one measure: Measure the impact of the protocol on general satisfaction of stay in outpatient surgery on day 7 with a Visual Analogue Scale Satisfaction sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: CHU de Liège city: Liège state: Wallonie zip: 4000 country: Belgium lat: 50.63373 lon: 5.56749 hasResults: False
nctId: NCT06268574 id: RIVER-52 briefTitle: Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML acronym: RIVER-52 overallStatus: RECRUITING date: 2024-01-23 date: 2026-02 date: 2026-09 date: 2024-02-20 date: 2024-02-20 name: Ryvu Therapeutics SA class: INDUSTRY briefSummary: The goal of this study is to assess the safety, tolerability, anti-tumor activity (efficacy), pharmacokinetics (PK), and pharmacodynamics (PD) of the agent RVU120 when administered to adult patients with relapsed or refractory acute myeloid leukemia (AML) or relapsed or progressing high-risk myelodysplastic syndrome (HR-MDS) and who have no alternative therapies available. The study consists of two parts. Part 1 will assess the safety and tolerability of the dosages given and the level of anti-tumor activity or clinical response. Based on the results from part 1 the study will continue to enrol patient into Part 2 which will continue to evaluate safety and tolerability and anti-tumor activity in a larger number of patients. conditions: Acute Myeloid Leukemia (AML) conditions: High-risk Myelodysplastic Syndrome studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Single Group Assignment primaryPurpose: TREATMENT masking: NONE count: 94 type: ESTIMATED name: RVU120 measure: Complete Remission (CR), with and without measurable residual disease (MRD) measure: Overall response rate measure: Duration of response measure: Progression-free survival measure: Overall survival measure: Incidence of Adverse Events (Safety and Tolerability) measure: Percentage of participants bridged to hematopoietic stem cell transplantation measure: Maximum Plasma Concentration (Cmax) measure: Maximum Plasma Concentration (Tmax) measure: Area Under the Concentration Time-Curve (AUC) measure: Impact of treatment on hematological malignancy patient-reported outcomes (HM-PRO) measure: Impact of treatment on health-related quality of life (QOL-E) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: MTZ Clinical Research status: RECRUITING city: Warszawa state: Mazowieckie Województwo zip: 02-172 country: Poland name: Krzysztof Mądry role: CONTACT phone: +48 22 572 59 59 email: info@pratia.com name: Krzysztof Mądry, MD role: PRINCIPAL_INVESTIGATOR lat: 52.22977 lon: 21.01178 facility: MICS Centrum Medyczne Toruń status: RECRUITING city: Toruń zip: 87-100 country: Poland name: Dominik Chraniuk role: CONTACT phone: +48 56 300 43 email: d.chraniuk@naszlekarz.pl name: Dominik Chraniuk, MD role: PRINCIPAL_INVESTIGATOR lat: 53.01375 lon: 18.59814 hasResults: False
nctId: NCT06268561 id: IRBN852023/CHUSTE briefTitle: Ozurdex Endophtamitis Cohort, Prognostic Assessment at 12 Months overallStatus: RECRUITING date: 2023-06-05 date: 2024-06 date: 2024-06 date: 2024-02-20 date: 2024-02-20 name: Centre Hospitalier Universitaire de Saint Etienne class: OTHER briefSummary: OZURDEX endophthalmitis is a rare and potentially very serious pathology. Different treatments can be carried out early and change the functional prognosis of the patient. conditions: Endophthalmitis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 8 type: ESTIMATED name: Visual acuity analysis name: Intraocular pressure analysis name: Analysis of optical coherence tomography (OCT) images name: Analysis of retinograms measure: Visual acuity measure: IOP measured in mmHg by tonometer and confirmed with Goldman Applanation measure: Tomography measure: Resumption of intravitreal therapy sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: CHU Saint Etienne status: RECRUITING city: Saint-Étienne zip: 42000 country: France name: Thibaud GARCIN, MD PhD role: CONTACT phone: (0)477829662 phoneExt: +33 email: thibaud.garcin@chu-st-etienne.fr name: Thibaud GARCIN, MD PhD role: PRINCIPAL_INVESTIGATOR name: Henri PITEAU, resident role: SUB_INVESTIGATOR lat: 45.43389 lon: 4.39 hasResults: False
nctId: NCT06268548 id: P.T.REC/012/004790 briefTitle: Effect of Manual Diaphragmatic Activation on Diaphragm Function in Patients With Gastroesophageal Reflux Disease overallStatus: RECRUITING date: 2023-09-15 date: 2024-02-20 date: 2024-02-27 date: 2024-02-20 date: 2024-02-20 name: Cairo University class: OTHER briefSummary: This study was conducted to investigate Effect of manual diaphragmatic activation on diaphragm function in patients with gastroesophageal reflux disease conditions: Diaphragm Dysfunction studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 30 type: ESTIMATED name: Manual diaphragmatic activation measure: Diaphragm Excursion sex: ALL minimumAge: 20 Years maximumAge: 50 Years stdAges: ADULT facility: Faculty of physical therapy status: RECRUITING city: Giza zip: 12613 country: Egypt name: Nesreen Ghareb Mohamed, Professor role: CONTACT phone: 01002227242 email: nesreen.elnahas@pt.cu.edu.eg lat: 30.00808 lon: 31.21093 hasResults: False
nctId: NCT06268535 id: CaenUH_DL_1 briefTitle: Identification of Anticancer Drugs Associated With Heart Failure: a WHO Pharmacovigilance Database Analysis overallStatus: COMPLETED date: 2022-04-01 date: 2022-05-31 date: 2022-05-31 date: 2024-02-20 date: 2024-02-20 name: University Hospital, Caen class: OTHER briefSummary: Therapeutic advances have significantly improved the survival of patients with cancer. However, these novel therapies are associated with a concomitant increase in the prevalence of toxicity, including cardiovascular complications of cancer therapy.
Using VigiBase, the World Health Organization's (WHO) global pharmacovigilance database, the investigators aimed to assess the relationship between cancer therapy-related cardiac dysfunction and the administration of anti-cancer drugs. conditions: Heart Failure conditions: Cancer, Therapy-Related studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 3406383 type: ACTUAL name: Cancer therapy with FDA and/or EMA approval on the 31st March 2022 measure: Disproportionality individual case data analysis between heart failure of cardiac dysfunction and cancer therapies measure: Description of the population of patients having a heart failure of cardiac dysfunction event with cancer therapies measure: Description of the pathologies (cancer) for which the incriminated drugs have been prescribed measure: Description of the drug-drug interactions associated with adverse events sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Caen University Hospital city: Caen country: France lat: 49.18585 lon: -0.35912 hasResults: False